BioSpace News Archive

YS Biopharma Co., Ltd. is pleased to announce that Noble Capital Markets has initiated equity research coverage on the Company with an “Outperform” rating and a 12-month price target of US$5.25 per share.

MBrace™ Therapeutics, Inc. announced the completion of an $85 million Series B financing, bringing the company’s total raised to $110 million.

Eyebiotech Limited (“EyeBio” or “the Company”), a privately held clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million.

IMUNON, Inc. announces that Jean Boyer, Ph.D., vice president of preclinical research and development, will highlight the Company’s vaccine development work in a presentation at the Vaccines Summit-2023 underway in Boston.

XBiotech announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

Shuttle Pharmaceuticals Holdings, Inc. today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

TRex Bio, Inc. today announced the selection of development candidate TRB-061, an agonist targeting TNF receptor 2 (TNFR2). TRB-061 expands regulatory T cells (Tregs) to restore homeostasis in the tissue at the site of inflammation.

Zeteo Tech, Inc. announced the issuance of U.S. Patent No. 11658021, titled “Systems and Methods of Rapid and Autonomous Detection of Aerosol Particles.”.

Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it has successfully submitted on November 9, 2023

TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).